STAAR Surgical (NASDAQ:STAA) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Tuesday, BidAskClub reports.

Several other research analysts have also recently weighed in on the stock. Canaccord Genuity restated a “buy” rating and set a $38.00 price target (down from $43.00) on shares of STAAR Surgical in a report on Monday, May 6th. Zacks Investment Research upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a report on Wednesday, May 1st. Finally, ValuEngine upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $40.33.

STAAR Surgical stock opened at $26.41 on Tuesday. STAAR Surgical has a fifty-two week low of $21.70 and a fifty-two week high of $54.00. The stock has a market cap of $1.17 billion, a P/E ratio of 94.32 and a beta of 2.23. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.83 and a current ratio of 5.41.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.06. STAAR Surgical had a net margin of 4.44% and a return on equity of 13.22%. The business had revenue of $32.58 million for the quarter, compared to analysts’ expectations of $32.40 million. During the same period in the previous year, the company earned $0.01 earnings per share. As a group, research analysts anticipate that STAAR Surgical will post 0.33 earnings per share for the current year.

In other STAAR Surgical news, CEO Caren L. Mason sold 7,500 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $36.25, for a total value of $271,875.00. Following the transaction, the chief executive officer now directly owns 44,013 shares in the company, valued at $1,595,471.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Broadwood Partners, L.P. bought 100,000 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was bought at an average price of $22.23 per share, for a total transaction of $2,223,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 17,730 shares of company stock worth $655,538. 3.90% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kayne Anderson Rudnick Investment Management LLC boosted its stake in STAAR Surgical by 54.2% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 121,575 shares of the medical instruments supplier’s stock valued at $4,156,000 after acquiring an additional 42,739 shares during the last quarter. Marshall Wace North America L.P. boosted its stake in STAAR Surgical by 27.1% in the first quarter. Marshall Wace North America L.P. now owns 14,481 shares of the medical instruments supplier’s stock valued at $495,000 after acquiring an additional 3,086 shares during the last quarter. Marshall Wace LLP boosted its stake in STAAR Surgical by 32.4% in the first quarter. Marshall Wace LLP now owns 201,530 shares of the medical instruments supplier’s stock valued at $6,891,000 after acquiring an additional 49,363 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in STAAR Surgical by 418.9% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 119,869 shares of the medical instruments supplier’s stock valued at $4,098,000 after acquiring an additional 96,768 shares during the last quarter. Finally, Zebra Capital Management LLC boosted its stake in STAAR Surgical by 11.7% in the first quarter. Zebra Capital Management LLC now owns 7,091 shares of the medical instruments supplier’s stock valued at $242,000 after acquiring an additional 740 shares during the last quarter. Hedge funds and other institutional investors own 89.59% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Recommended Story: What is the cash asset ratio?

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.